Nasal Decongestion and Obstructive Sleep Apnea

University of Zurich12 enrolled

Overview

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Obstructive Sleep Apnea Syndrome Rhinitis

Interventions

xylometazolineDRUG

xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index \>10/h) * Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months) Exclusion Criteria: * Nasal surgery within the last 6 months * Current treatment with nasal decongestants or topical steroids * Sleep disorders other than obstructive sleep apnea * Internal medical or psychiatric disorders that interfered with sleep

Locations (2)

Pulmonary Division, University Hospital Zurich, Switzerland

Zurich, Switzerland

Pulmonary Division, University Hospital Zurich

Zurich, Switzerland

Outcomes

Primary Outcomes

sleep related breathing disturbances sleep efficiency daytime sleepiness

Time frame: at end of one week treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.